Q4 EPS Estimates for Zimmer Biomet Lowered by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Zacks Research cut their Q4 2025 earnings per share estimates for shares of Zimmer Biomet in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.37 per share for the quarter, down from their prior estimate of $2.38. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the company posted $1.65 EPS. The business’s revenue was up 4.1% on a year-over-year basis.

Several other analysts also recently commented on ZBH. BTIG Research lowered their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. UBS Group dropped their price objective on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research note on Thursday, August 8th. Truist Financial lifted their price objective on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Finally, Oppenheimer decreased their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Stock Up 1.2 %

Shares of Zimmer Biomet stock opened at $112.02 on Thursday. Zimmer Biomet has a one year low of $101.47 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The stock’s 50-day moving average is $107.18 and its 200 day moving average is $109.50. The firm has a market cap of $22.30 billion, a price-to-earnings ratio of 21.30, a PEG ratio of 2.03 and a beta of 1.02.

Institutional Trading of Zimmer Biomet

Several large investors have recently bought and sold shares of the company. BLB&B Advisors LLC boosted its position in Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 100 shares in the last quarter. FWG Holdings LLC boosted its position in shares of Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after purchasing an additional 101 shares in the last quarter. Financial Advocates Investment Management boosted its position in shares of Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares in the last quarter. M&R Capital Management Inc. boosted its position in shares of Zimmer Biomet by 14.1% in the 3rd quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after purchasing an additional 105 shares in the last quarter. Finally, Mill Creek Capital Advisors LLC boosted its position in shares of Zimmer Biomet by 5.1% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 106 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.